The short version of Stenabolic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
watch glass A circular, concave piece of glass commonly used in chemistry laboratories as a working surface for various purposes, such as evaporating liquids, holding solids while they are being weighed, heating small amounts of a substance, or as a cover for a beaker.
. The Michaelis constant KM is experimentally defined as the concentration at which the rate of the enzyme reaction is half Vmax, which can be verified by substituting [S] = KM into the Michaelis–Menten equation and can also be seen graphically. If the rate-determining enzymatic step is slow compared to substrate dissociation (
In group 14, both metallic and covalent bonding become possible. In a diamond crystal, covalent bonds between carbon atoms are strong, because they have a small atomic radius and thus the nucleus has more of a hold on the electrons. Therefore, the bonding orbitals that result are much lower in energy than the antibonding orbitals, and there is no overlap, so electrical conduction becomes impossible: carbon is a nonmetal. However, covalent bonding becomes weaker for larger atoms and the energy gap between the bonding and antibonding orbitals decreases. Therefore, silicon and germanium have smaller band gaps and are semiconductors at ambient conditions: electrons can cross the gap when thermally excited. (Boron is also a semiconductor at ambient conditions.) The band gap disappears in tin, so that tin and lead become metals. As the temperature rises, all nonmetals develop some semiconducting properties, to a greater or lesser extent depending on the size of the band gap. Thus metals and nonmetals may be distinguished by the temperature dependence of their electrical conductivity: a metal's conductivity lowers as temperature rises (because thermal motion makes it more difficult for the electrons to flow freely), whereas a nonmetal's conductivity rises (as more electrons may be excited to cross the gap). Elements in groups 15 through 17 have too many electrons to form giant covalent molecules that stretch in all three dimensions.
There are many challenges surrounding human remains accessioned by museums, including legal complications involved in dealing with human remains, involvement of living relatives or tribes, and potential repatriation and issues such as the Native American Graves Protection and Repatriation Act of 1990 (NAGPRA). NAGPRA requires any federal or federally-funded institution, with the exception of the Smithsonian Institution, to submit full inventories of their Native American funerary and sacred objects and human remains and to repatriate these objects to their tribe of origin should a request be made to do so. Should a museum possess human remains which have a direct living relative or group (Native American or otherwise), it is their ethical obligation to involve these individuals in the care and treatment of the remains. Acquisition of human remains by museums can happen in a number of ways, some of which are considered to be unethical today. Many museums have human remains in their collections which have been there for over a hundred years, in which case they may likely have been acquired in ethically or morally unsound ways. This has led to growing concerns that the display of human remains has become depersonalised, by continuing to keep them in collections. Most institutions and museum associations have their own policies on the acquisition of human remains. Some guidelines for the care of human remains including acceptable means of acquisition can be found below.
Sources: en.wikipedia.org
Moreover, there are some challenges in fabricating and applying graphene oxide based nanofilters for water desalination. The challenges include mechanical instability if nanofilters are in the form of nanosheets, cost strategy, surface flaws, and assembly. Therefore, there are more scopes in this area of research to be worked on for the betterment of the society.
While Seaborg applied for funding, Harvey worked on the einsteinium target, while Thomson and Choppin focused on methods for chemical isolation. Choppin suggested using α-hydroxyisobutyric acid to separate the mendelevium atoms from those of the lighter actinides. The initial separation was done by a recoil technique suggested by Albert Ghiorso: the einsteinium was placed on the opposite side of the target from the beam, so that the momentum of the recoiling mendelevium atoms would allow them to leave the target and be caught on a gold catcher foil behind it. This recoil target was made by an electroplating technique, developed by Alfred Chetham-Strode. This technique gave a very high yield, which was absolutely necessary when working with such a rare and valuable product as the einsteinium target material. The recoil target consisted of 109 atoms of 253Es which were deposited electrolytically on a thin gold foil. It was bombarded by 41 MeV alpha particles in the Berkeley cyclotron with a very high beam density of 6×1013 particles per second over an area of 0.05 cm2. The target was cooled by water or liquid helium, and the foil could be replaced. Initial experiments were carried out in September 1954. No alpha decay was seen from mendelevium atoms; thus, Ghiorso suggested that the mendelevium had all decayed by electron capture to fermium-256, correctly believed to decay primarily by fission, and that the experiment should be repeated, this time searching for those spontaneous fission events. This version of the experiment was performed in February 1955.
Francis Joseph Donnelly. For services to Disability Sport and to the community in Northern Ireland. Nilesh Bhasker Dosa. Founder, icanyoucantoo. For services to Social Equality. George David Dowell. Owner, Worthing Football Club. For services to Association Football and to Disability Awareness. Elissa Rebecca Louise Downie. For services to Gymnasts and to the Sport of Gymnastics. Rebecca Lauren Downie. For services to Gymnasts and to the Sport of Gymnastics. Spencer Drury. Lately Councillor, Royal Borough of Greenwich. For Political and Public Service. James Michael Duffy. Lately Child Protection Manager, Lothian and Borders Police and Police Service of Scotland. For services to Children. Giles Duley. Founder, Legacy of War Foundation. For services to Survivors of Conflict. Mary Alexandra Earps. For services to Association Football. Dr. Gillian Mary Eatough. Lately Chief Executive Officer, Learning Community Trust. For services to Education. Captain Thomas David Eccles. Fisheries Officer, Department of Agriculture, Environment and Rural Affairs. For services to Fisheries, Environment and to Maritime Safety. Linda Jacqueline Edmunds. Consultant Nurse, Heart Failure and Cardiac Rehabilitation, Aneurin Bevan University Health Board. For services to Cardiac Rehabilitation and Heart Failure. Professor Anthony David Edwards. Professor of Paediatrics and Neonatal Medicine, King's College London. For services to Health Research. Huw William Edmond Edwards. Founder Member, Monmouth Male Voice Choir. For services to Music and to Charity. Dr. Alice Elizabeth Ellis (Alice Hartley).
== Detrital zircon extraction == After rock samples are collected, they are cleaned, chipped, crushed and milled through standardized procedures. Then, detrital zircons are separated from the fine rock powder by three different ways, namely gravity separation using water, magnetic separation, and gravity separation using heavy liquid. In the process, grains are also sieved according to their size. The commonly used grain size for detrital zircon provenance analysis is 63–125 μm, which is equivalent to fine sand grain size.
Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour. Common side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended. Famotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2023, it was the 33rd most commonly prescribed medication in the United States, with more than 16 million prescriptions.
Sources: en.wikipedia.org
== History == Harith Rajagopalan, MD, PhD, and Jay Caplan established Fractyl Health, initially named Fractyl Laboratories, in 2010. The company's Revita device gained CE marking in April 2016 and became commercially available in the UK in January 2020. In April 2021, the US Food and Drug Administration (FDA) gave Revita breakthrough device designation to treat type 2 diabetes. The company changed its name to Fractyl Health in June 2021. In April 2022, the FDA approved an investigational device exemption trial for Revita. It became available commercially in Germany in early 2023. The FDA issued additional breakthrough device designation to Revita in July 2024 for weight maintenance in certain people with type 2 diabetes or obesity. Fractyl had an initial public offering on the Nasdaq in February 2024. As of February 2025, the company's REMAIN-1 study is evaluating Revita for patients with obesity to support weight maintenance after use of a GLP-1 drug. In January 2025, Fractyl announced it would focus research for Revita on obesity and people on GLP-1s, citing rising demand driven by the popularity of GLP-1s. The company also laid off some employees focused on type 2 diabetes treatment.
=== Macrocyclic chiral stationary phases === Macrocyclic chiral stationary phases consist of a silica support, on which macrocyclic antibiotic molecules are bonded. The commonly used macrocyclic antibiotics include rifamycin, glycopeptides (for example, avoparcin, teicoplanin, ristocetin A, vancomycin, and their analogs), polypeptide antibiotic thiostrepton, and aminoglycosides (for example, fradiomycin, kanamycin, and streptomycin). The macrocyclic antibiotics interact with the analyte through hydrogen bonds, dipole-dipole interactions with the polar groups of the analyte, ionic interactions and π-π interactions.
As a precaution, patients undergoing permanent brachytherapy are advised not to hold small children immediately after treatment and not to be in the vicinity of pregnant women, since low-dose radioactive sources (seeds) remain in the body after treatment with permanent brachytherapy. This is to protect the particularly radiation-sensitive tissues of a fetus or infant.
==== Peptidoglycan recognition proteins ==== PGLYRPs are conserved from insects to mammals. Mammals produce four secreted soluble peptidoglycan recognition proteins (PGLYRP-1, PGLYRP-2, PGLYRP-3 and PGLYRP-4) that recognize muramyl pentapeptide or tetrapeptide. They can also bind to LPS and other molecules by using binding sites outside of the peptidoglycan-binding groove. After recognition of peptidoglycan, PGLYRPs activate polyphenol oxidase (PPO) molecules, Toll, or immune deficiency (IMD) signalling pathways. That leads to production of antimicrobial peptides (AMPs). Each of the mammalian PGLYRPs display unique tissue expression patterns. PGLYRP-1 is mainly expressed in the granules of neutrophils and eosinophils. PGLYRP-3 and 4 are expressed by several tissues such as skin, sweat glands, eyes or the intestinal tract. PGLYRP-1, 3 and 4 form disulphide-linked homodimers and heterodimers essential for their bactericidal activity. Their binding to bacterial cell wall peptidoglycans can induce bacterial cell death by interaction with various bacterial transcriptional regulatory proteins. PGLYRPs are likely to assist in bacterial killing by cooperating with other PRRs to enhance recognition of bacteria by phagocytes. PGLYRP-2 is primarily expressed by the liver and secreted into the circulation. Also, its expression can be induced in skin keratinocytes, oral and intestinal epithelial cells. In contrast with the other PGLYRPs, PGLYRP-2 has no direct bactericidal activity.
== Business == Kinohimitsu has a distribution network of more than 6,000 points of sales in Asia, namely China, Singapore, Malaysia, Vietnam, Thailand, Cambodia and Indonesia. Kinohimitsu's products are sold in pharmacies, supermarkets and convenience stores. In 2014, Kinohimitsu opened its first beauty counter in Singapore at OG Orchard Point.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.